Quanticate doubles its footprint in India
New center of excellence to support further development of collaborative, long-term partnerships with leading pharmaceutical companies.
Quanticate, a global data-focused clinical research organisation (CRO), is further expanding its service offering into India with the opening of a new office.
Strategically located in Bangalore, with access to the country’s extensive talent pool in the pharmaceutical services industry, the new office will be a base from which Quanticate will broaden its capabilities for the management, analysis and reporting of data from clinical trials and post-marketing surveillance.
The decision to open the office follows a very successful year for Quanticate, which saw an increase in sales driving the demand for more resources both in India and further afield. The new 16,500-sq. ft. premises doubles the company’s current footprint in the country.
Praveen Dass, VP of clinical data management and head of Indian operations at Quanticate explains: “By expanding our presence in India, we are able to increase our capacity meaning we can cater for more clients on a larger scale.
“We have an ambitious growth strategy to deliver over the next 5 years, which aims to employ over 60 new members of staff in the coming months. Our new office provides the perfect platform for this growth and marks an important milestone in our journey.”
As the company’s new operational center of excellence, the facility will also help Quanticate to provide outstanding customer service for its global client base and support further development of collaborative, long-term partnerships with leading pharmaceutical companies.
The CROs increased presence in the region has recently allowed Quanticate to engage with a diverse range of industry-specific groups, including the Society for Clinical Data Management (SCDM) India and Pharmaceutical Users Software Exchange (PhUSE) India. The company has representatives on the steering committee and co-chaired the first Society for Clinical Data Management (SCDM) Single Day Event (SDE).
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance